China Successfully Implanted Retrievable Transcatheter Aortic Valve in Humans
The first human implantation of the VenusA Plus, retrievable valve system was successfully completed at the Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU) on November 27, 2017.
Venus Medtech has become China’s first company to provide a retrievable interventional cardiac valve system. Prof. Wang Jian’an, president of SAHZU, announced first successful human implantation of a retrievable transcatheter aortic valve.
The operation was conducted on 76 year old female patient who was diagnosed with severe aortic valve stenosis and defined as a high-risk surgical patient. The cardiology team discussed and defined the patient’s anatomical features as a bicuspid aortic valve and asymmetric calcification, which raised the risk of dislocation during the valve implantation. Retrievable system was the most suitable treatment for the patient, according to the physicians.
The retrievable system allows the valve to withdraw and reposition after release, avoiding adverse events, which occur as a result of a poor implant position and mismatch of the implanted valve. It includes valve translocation, severe paravalvular leakage, a negative impact on the bicuspid aortic valve, and high degree atrioventricular block caused by conduction bundle compression. The system also reduces the complexity of the procedure, which helps to promote the adoption and application of TAVR technology.
“SAHZU’s medical team was closely working with Zhejiang Province’s Cardiac Valve Research Institute and Venus Medtech’s R&D team to study, develop, and produce the heart valve products. The collaboration began with the VenusA-Valve and has led to the success for VenusA Plus,” said professor Wang. “The product is a next-generation TAVR valve that delivers good performance in terms of release, retrievable stability, controllability and passing ability, thus offering great potential when it comes to clinical applications.” Wang added.
The successful human implantation of VenusA Plus took place four months after the launch of China’s first TAVR valve VenusA-Valve. “Venus Medtech has continuously achieved technological breakthroughs. We plan to roll out more innovative products going forward, demonstrating the company’s strong competence in innovation and its ongoing commitment to serving patients,” said Zi Zhenjun, CEO of Venus Medtech.
You may be interested
Increasing Prevalence Of Diabetes And Rising Geriatric Population Will Drive The Overall Disposable Insulin Pen MarketMohit Joshi - October 17, 2018
The Disposable Insulin Pen Market is expected to have a highly positive growth outlook from 2018-2026 according to a recently released research report. The report has been…
Medical Electrodes Market Is Expected To Record Highest Growth Rate Due To Increasing Prevalence Of Cardiology And Neurological DiseasesMohit Joshi - October 17, 2018
The Medical Electrodes Market is expected to have a highly positive growth outlook from 2018-2026 according to a recently released research report. The report has been added…
Extracorporeal Shock Wave Lithotripsy Market Is Being Fuelled By Rise In Incidence Of Kidney StonesMohit Joshi - October 17, 2018
The Extracorporeal Shock Wave Lithotripsy Market is expected to have a highly positive growth outlook from 2018-2026 according to a recently released research report. The report has…